Tuberculosis cost-effectiveness of therapy
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Tuberculosis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Tuberculosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Cost effectiveness of therapy
While measurements of morbidity and mortality are key considerations for estimating the burden of disease in populations, they provide an incomplete picture of the adverse impact of ill health on human welfare. In particular, the economic consequences of poor health can be substantial.
Analysis of the economic impact of ill-health addresses a number of policy questions concerning the consequences of disease or injury. Some of these questions relate to the microeconomic level of households, firms or government – such as the impact of ill-health on a household’s income or a firm’s profits – while others relate to the macroeconomic level, including the aggregate impact of a disease on a country’s current and future gross domestic product (GDP).
WHO proposes a defined conceptual framework within which the economic impact of diseases and injuries can be considered and appropriately estimated. [1]
| Intervention | Yearly costs with 95% coverage level |
|---|---|
| Minimal DOTS | 366.3 million $ |
| Full DOTS | 612.2 million $ |
| Minimal DOTS with resistant cases | 495.9 million $ |
| Full combination | 739.4 million $ |